GlassScriptPhysician profile
Sulay Patel
NPI 1265798763
$20,136.82
in general payments reported to CMS, 2019-2025
23 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $11K · 2021: $1,135 · 2022: $3,211 · 2023: $1,344 · 2024: $2,778 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Travel and Lodging: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.11 |
| Travel and Lodging | $1,455.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $10,746.07 | 2019-2020 | |
| Abbott Laboratories | $2,146.23 | 2021-2023 | Cardiomems, Mitraclip |
| Edwards Lifesciences Corporation | $2,060.85 | 2020-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $1,878.81 | 2022-2025 | Impella |
| Medtronic, INC. | $1,145.44 | 2021-2025 | Resolute Onyx, Corevalve Evolut R |
| Boston Scientific Corporation | $563.94 | 2021-2025 | Watchman Flx, Avvigo Guidance System |
| Biosense Webster, INC. | $344.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $149.99 | 2023 | Xarelto |
| W. L. Gore & Associates, INC. | $138.01 | 2021 | |
| Pfizer INC. | $129.38 | 2023-2025 | |
| Osprey Medical INC | $127.00 | 2019 | |
| Asahi Intecc USA, INC. | $125.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $121.82 | 2023 | Opsumit, Uptravi |
| Cardiva Medical, INC. | $101.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $92.05 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $80.54 | 2024 | Wainua |
| Cardiovascular Systems INC. | $58.65 | 2019-2022 | |
| Atricure, INC. | $33.82 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.08 | 2023 | Lifevest |
| Cvrx, INC. | $22.09 | 2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $17.59 | 2025 | Camzyos |
| Heartflow, INC. | $16.97 | 2025 | |
| Angiodynamics, INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sulay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.